Andere talen Hyloris Pharmaceuticals SA

Aandelen

HYL

BE0974363955

Farmaceutische producten

Real Time Euronext Bruxelles Andere beurzen 15:51:34 22-01-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
5,560 ^EUR	-2,11%		-6,71%	-14,98%

04/01	Weinig spektakel op Brusselse beurs	AM
30/12	Hyloris meldt positieve resultaten met Valacyclovir	AM

Andere talen

Hyloris Pharmaceuticals : Degroof Petercam’s Virtual Healthcare Conference	10:53
Hyloris Pharmaceuticals : Regulated Information Information on Voting Rights and Denominator FRENCH VERSION	09/01
Hyloris :en forme après un accord de licence et un nouveau directeur financier	09/12
Hyloris Pharmaceuticals : Inside Information Hyloris Announces Partnership with Rosemont Pharmaceuticals for Valacyclovir Oral Suspension in the U.S. ENGLISH VERSION	09/12
Hyloris Pharmaceuticals : Inside Information Hyloris Announces Partnership with Rosemont Pharmaceuticals for Valacyclovir Oral Suspension in the U.S. FRENCH VERSION	09/12
Hyloris Pharmaceuticals : Regulated Information Hyloris Appoints Christophe Maréchal as Chief Financial Officer ENGLISH VERSION	09/12
Hyloris Pharmaceuticals : Regulated Information Hyloris Appoints Christophe Maréchal as Chief Financial Officer FRENCH VERSION	09/12
Hyloris Pharmaceuticals : 2024 Half Year Results - English	17-10-24
Hyloris Pharmaceuticals : 2024 Rapport Semestriel - Français	17-10-24
Hyloris Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2024	16-10-24
Hyloris : 27,4 millions d'euros de trésorerie, levée de fonds envisagée	07-10-24
Hyloris Pharmaceuticals : Investor Presentation - KBC Event	24-09-24
That's not so bad, is it?	08-07-24
L'Europe hésite avec les incertitudes politiques en France	08-07-24
En Direct des Marchés : Veolia, Safran, Carmat, Boeing, Apple, Holcim, Samsung Electronics...	08-07-24
Ce n'est pas si mal ?	08-07-24
Borsa di Italia: Non è così male, vero?	08-07-24
Belgian finance regulator issues warning about Hyloris Pharmaceuticals	05-07-24
Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024	14-03-24
Hyloris Présente ses Résultats Annuels pour 2023 et ses Perspectives	14-03-24
Hyloris Reports Full Year Results for 2023 & Provides Business Outlook	14-03-24
Communiqué à la requête de la FSMA sur les transactions avec QliniQ	14-03-24
Communication at the request of the FSMA on the transactions with Qliniq	14-03-24
Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023	14-03-24
Communication at the request of the FSMA on the transactions with Qliniq	14-03-24

Word de lid om toegang te krijgen tot meer nieuws.

Gratis inschrijven

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Hyloris Pharmaceuticals SA

Aandelen

HYL

BE0974363955

Farmaceutische producten

Andere talen

Filters